

## BioMed Valley Discoveries Announces Poster Presentations on Ulixertinib (BVD-523) at the AACR Annual Meeting 2022

March 22, 2022

KANSAS CITY, Mo., March 22, 2022 – BioMed Valley Discoveries (BVD), a clinical-stage biotechnology company, announced today they will present four posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana. All four posters focus on the continued development of [ulixertinib \(BVD-523\)](#), the first-in-class and best-in-class ERK1/2 inhibitor. In addition, two collaborators will present additional data on ulixertinib.

### BVD Poster Presentation Details:

**Abstract Number:** 415

Title: [The characterization of in vitromodels demonstrating a significant delay of acquired resistance to ulixertinib \(ERK1/2\)](#)

Date/Time: Sunday, April 10, 2022 1:30 PM – 5:00 PM

Session: Cancer Drug Resistance and Reversal of Resistance

Location: New Orleans Convention Center, Poster Section 25

**Abstract Number:** 404

Title: [Identification of combination partners to combat acquired resistance to ulixertinib \(ERK1/2 inhibitor\) using transcriptomics](#)

Date/Time: Sunday, April 10, 2022 1:30 PM – 5:00 PM

Session: Cancer Drug Resistance and Reversal of Resistance

Location: New Orleans Convention Center, Poster Section 25

**Abstract Number:** 1057

Title: [Significant efficacy demonstrated with the combination of ulixertinib \(ERK1/2 inhibitor\) and CDK4/6 inhibitors in MAPK altered models](#)

Date/Time: Monday, April 11, 2022 9:00 AM - 12:30 PM CST

Session: Combinations

Location: New Orleans Convention Center, Poster Section 21

**Abstract Number:** 4022

Title: [ERK1/2 inhibitor ulixertinib demonstrates activity in atypical \(non-V600\) BRAF mutant models](#)

Date/Time: [Wednesday, April 13, 2022 9:00 AM – 12:30 PM](#)

Session: Molecular Pharmacology

Location: New Orleans Convention Center, Poster Section 26

### Collaborator Poster Presentation Details

**Abstract Number:** 5221

Title: [The first-in-class ERK inhibitor ulixertinib \(BVD-523\) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics](#)

Session: Pediatric Cancer: Clinical Investigations

Location: E-Poster Website

**Abstract Number:** 5333

Title: [Pancreatic cancer enhances HER2 signaling through DUSP6 to circumvent therapeutic MAPK inhibition](#)

Session: Drug Resistance

Location: E-Poster Website

Abstracts and full session details are currently available on the [AACR meeting website](#). Posters will be available online at [www.biomed-valley.com/news/#events-presentations](http://www.biomed-valley.com/news/#events-presentations) following the presentations.

About Ulixertinib (BVD-523): Ulixertinib is a first-in class and best-in class small molecule inhibitor of extracellular signal-regulated kinase (ERK) family kinases (ERK1 and ERK2) that is being developed as a novel anti-cancer drug. ERK kinases are downstream components of the mitogen-activated protein kinase (MAPK) signaling cascade (RAS-RAF-MEK-ERK). Ulixertinib has demonstrated promising early efficacy for patients with tumors harboring alterations in the MAPK pathway, including atypical (non-V600) BRAF alterations, for which there are currently no approved targeted agents.

About BioMed Valley Discoveries (BVD): BioMed Valley Discoveries is a clinical stage biotechnology company focused on addressing unmet medical needs in a variety of therapeutic and diagnostic areas. In addition to the ERK inhibitor, BVD's portfolio includes an oncolytic bacteria that has completed enrollment for a Phase I study, and two early-stage antibodies targeting the tumor microenvironment.

Operating since 2007, BioMed Valley Discoveries was established by Jim Stowers Jr., founder of the asset management firm [American Century Investments](#), and his wife Virginia, to advance new medical innovations to improve the lives of patients with difficult-to-treat diseases. BVD is owned by a supporting organization of the [Stowers Institute for Medical Research](#), a non-profit, basic biomedical research organization. Since 2000, the Stowers Institute has received over \$1.5 billion in dividend payments from American Century. The Institute has invested a portion of its institutional funds in BVD, whose profits accrue to the benefit of the Institute. For more information, visit [www.biomed-valley.com](http://www.biomed-valley.com)

**Media Contact:**

Jennifer Pawlosky, Vice President of Communications  
816-389-8848  
[mediacontact@biomed-valley.com](mailto:mediacontact@biomed-valley.com)